Filing Flows › Cytosorbents (CTSO) › Q2 2025
Cytosorbents (CTSO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Cytosorbents (CTSO) reported revenue of $9.6M for the second quarter 2025 (Q2 2025), +9% from a year earlier and +10% from the quarter before. Operating margin was -37.6%, net earnings $1.9M (20.3% of revenue).
Cytosorbents, Q2 2025: revenue $9.6M (+9% year over year), operating margin -37.6%, net earnings $1.9M, operating cash flow −$1.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.6M | +10% | +9% |
| Operating profit | −$3.6M | — | — |
| Net earnings | $1.9M | — | — |
| Operating cash flow | −$1.5M | — | — |
What changed
Revenue was $9.6M in Q2 2025, up 9% year over year and up 10% from the previous quarter.
Gross margin was 70.9%, down 2.7 points from a year earlier. Operating costs exceeded revenue by $3.6M, an operating margin of -37.6%. Operating expenses grew 4% against revenue growth of 9%. Net earnings were $1.9M. The effective tax rate was 0.0%. Non-operating items added $5.6M, 286% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$1.5M. Non-cash charges added back $404K of depreciation and amortization and $571K of share-based compensation. Working capital and other items used $4.4M. Capital expenditures of $37K exceeded it, leaving free cash flow of −$1.5M.
Questions
What was Cytosorbents' revenue in the second quarter 2025?
Cytosorbents (CTSO) reported revenue of $9.6M for the second quarter 2025 (Q2 2025), +9% from a year earlier and +10% from the quarter before.
Was Cytosorbents profitable in the second quarter 2025?
Operating loss was $3.6M (-37.6% of revenue) and net earnings $1.9M.
Source: Cytosorbents 10-Q on SEC EDGAR.